David A. Rizzieri
David A. Rizzieri is an Associate Professor of medicine and the Director of the Hematologic Malignancy Program in the Division of Cellular Therapy, Department of Medicine, at Duke University Medical Center in Durham, NC, USA. Dr. Rizzieri earned his medical degree at the University of Rochester School of Medicine and Dentistry in NY, USA, and completed an internship and residency at the University of Rochester in Rochester, NY, USA. He completed a fellowship at the Division of Oncology and Hematology at Duke University Medical Center in Durham. Board certified in oncology, Dr. Rizzieri is a Member of the American Society of Hematology, the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Society of Blood and Marrow Transplantation. He is also the Clinical Chair or Cochair of national CALGB leukemia/lymphoma trials involving patients with Burkitt’s, myelodysplastic syndromes, and follicular lymphoma. He has focused his clinical/translational research efforts on the care and treatment of patients with leukemia and lymphoma. He designed novel approaches for the care of patients using monoclonal antibodies with nonmyeloablative allogeneic therapy to optimize a less toxic regimen for transplant of patients with hematologic malignancies using haploidentical as well as matched siblings. In addition, he has led the development of antistromal therapy in lymphoma using new antibodies targeting the stromal protein tenascin and targeting acute myelogenous leukemia by linking diphtheria to an antibody to the IL-3 receptor. Moreover, he leads the development and oversight of all clinical trials in adults with hematologic malignancies conducted in the Duke Comprehensive Cancer Center. Rizzieri has received many awards and honors including the Scholar in Clinical Research Grant from the Leukemia and Lymphoma Society and election to the American Society for Clinical Investigation.
Biography Updated on 7 April 2010